CliffBio
small molecule

PERSERIS KIT

RISPERIDONE

Loss of exclusivityFebruary 2028latest FDA-listed patent expiry
CompanyIndivior →View the full company profile on CliffBio

Drug detail

Brand namePERSERIS KIT
Active ingredientRISPERIDONE
Strength120MG
Dosage formFOR SUSPENSION, EXTENDED RELEASE
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusRX

Listed patents

PatentExpiresType
9180197February 2028product
11712475February 2028use U-3135
11013809February 2028product
9186413February 2028use U-543
10010612February 2028product
10376590February 2028use U-2608
11110093November 2026product
9597402September 2026product
10058554September 2026use U-2363
10406160June 2026product

More from Indivior

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PERSERIS KIT patent cliff — loss of exclusivity February 2028 | CliffBio